NICE vs SIGN: Management of Gout (2025) - A Clinical Comparison
This guide provides a detailed, factual comparison of the 2022 National Institute for Health and Care Excellence (NICE) guideline and the 2023 Scottish Intercollegiate Guidelines Network (SIGN) guideline for the management of gout. While both are evidence-based and aimed at UK practice, they differ in several key areas, reflecting evolving evidence and differing consensus. This comparison is designed to help clinicians navigate these differences and apply the guidance pragmatically in their practice.
See how this translates to practice: Explore our Clinical governance features, visit the Patient Safety Hub, or review Clinical Safety & Assurance for enterprise rollout.
Diagnosis and Assessment
NICE (NG219)
NICE places a strong emphasis on rapid, primary care-led diagnosis to prevent long-term joint damage.
- Diagnostic Approach: Recommends a clinical diagnosis based on a characteristic history (rapid onset, severe pain, erythema, resolution within days) and the presence of risk factors (e.g., hyperuricaemia, chronic kidney disease, diuretic use).
- Joint Aspiration: Advises against routinely aspirating joints during an acute attack if the diagnosis is clinically clear. Aspiration is reserved for diagnostic uncertainty, atypical presentations, or possible septic arthritis.
- Serum Urate: Cautions that serum urate levels may be normal during an acute attack and should not be used to rule out gout. Measurement is more reliable 4-6 weeks after the attack has fully resolved.
- Imaging: Does not recommend ultrasound or dual-energy CT (DECT) for routine diagnosis, suggesting they be considered only if the diagnosis is uncertain and aspiration is not possible or conclusive.
SIGN (SIGN 176)
SIGN aligns with NICE on clinical diagnosis but shows a greater willingness to use advanced techniques to confirm the diagnosis.
- Diagnostic Approach: Also supports clinical diagnosis but provides a more structured approach using scoring systems (e.g., the 2015 ACR/EULAR criteria) in complex cases.
- Joint Aspiration: Strongly recommends joint aspiration and microscopy for crystal identification to confirm the diagnosis wherever possible, even in typical presentations, as this is the diagnostic gold standard.
- Serum Urate: Similar advice to NICE regarding timing of measurement.
- Imaging: Is more positive about the role of imaging. Suggests that ultrasound can be a useful adjunct for diagnosis by identifying features like the double-contour sign or tophus, especially if aspiration is not feasible.
Key Difference: The major divergence is in the approach to diagnostic confirmation. NICE favours a pragmatic, clinical diagnosis in primary care to speed up management, while SIGN advocates more strongly for definitive confirmation via crystal identification or imaging to avoid misdiagnosis.
Treatment: Acute Attack and Urate-Lowering Therapy (ULT)
Managing the Acute Attack
Both guidelines are largely congruent.
- First-line: Both recommend an NSAID (e.g., naproxen, diclofenac), a COX-2 inhibitor (e.g., etoricoxib), or colchicine as first-line options, considering patient comorbidities and contraindications.
- Dosing: SIGN provides more specific, weight-based dosing for colchicine (500 mcg two to four times daily), whereas NICE is less prescriptive.
- Corticosteroids: Both recommend oral corticosteroids (e.g., prednisolone 30mg daily for 5 days) as an effective first-line option, particularly for patients with contraindications to NSAIDs/colchicine.
- Continuing ULT: Both agree that Urate-Lowering Therapy (ULT) should not be stopped during an acute attack.
Starting and Titrating Urate-Lowering Therapy (ULT)
This is an area of significant practical difference.
- NICE: Recommends offering ULT after the first attack, not waiting for recurrent disease. The goal is to prevent any further damage from the outset.
- SIGN: Recommends discussing and offering ULT after the first attack, but places a stronger emphasis on initiating it in patients with recurrent attacks, tophus, or chronic gouty arthritis. It is more conservative regarding a single, first episode.
- First-line ULT: Both recommend allopurinol as first-line treatment.
- Dosing & Titration:
- NICE: Advocates a "start low and go slow" approach. Start at 100mg daily (50mg in CKD stage 4/5) and titrate upwards in 100mg increments every 4-8 weeks until the target serum urate is achieved. This is to reduce the risk of flare-ups at initiation.
- SIGN: Also supports a "start low" approach but is generally more aggressive with titration, often using 100mg increments and suggesting a maximum dose of 900mg if needed, compared to NICE's 900mg being rarely required.
- Target Serum Urate: Both agree on a target of <360 μmol/L (<300 μmol/L in those with severe tophaceous disease).
- Prophylaxis: Both mandate offering prophylaxis against acute flares when starting ULT. NICE recommends colchicine (500 mcg twice daily) for up to 6 months; SIGN recommends it for at least 6 months.
Key Difference: The most critical difference is the timing of ULT initiation. NICE's recommendation to offer ULT after the first attack is a proactive, preventative strategy, whereas SIGN's approach is more traditional, focusing on patients with established, recurrent disease.
Special Situations
Chronic Kidney Disease (CKD)
- NICE: Provides detailed advice on dose adjustment for allopurinol based on eGFR. Recommends febuxostat as a second-line option if allopurinol is not tolerated or contraindicated, with no dose adjustment needed for mild-to-moderate CKD.
- SIGN: Similar recommendations but advises caution with febuxostat in patients with significant cardiac disease, reflecting MHRA guidance.
Refractory Gout
- Both guidelines recommend febuxostat as a second-line agent.
- NICE: Does not recommend uricosuric agents (e.g., probenecid, sulfinpyrazone) due to a lack of cost-effectiveness evidence within the NHS.
- SIGN: Does include uricosurics as potential options for patients intolerant of both allopurinol and febuxostat, particularly when administered by a specialist.
Practical Clinical Flow: A Hybrid Approach
For a UK clinician, a pragmatic synthesis of both guidelines might look like this:
- Acute Presentation: Diagnose clinically. Consider aspiration if doubt exists (aligning with SIGN) or if presentation is atypical. Treat promptly with NSAID, colchicine, or oral steroids.
- Post-Attack Review (4-6 weeks later): Measure serum urate. Discuss ULT. Strongly consider offering ULT after the first attack (as per NICE), especially with high serum urate, CKD, or diuretic use. If the patient declines, ensure they understand to return after a second attack.
- Initiating ULT: Start allopurinol at 100mg daily (50mg if eGFR <30). Simultaneously prescribe anti-inflammatory prophylaxis (e.g., colchicine 500 mcg BD) for 6 months.
- Titration & Monitoring: Check serum urate every 4-8 weeks. Titrate allopurinol in 50-100mg increments until target urate (<360 μmol/L) is achieved. Adhere to the "start low, go slow" principle to improve adherence and reduce flares.
- Long-term Management: Continue ULT for life. Review annually to reinforce adherence, monitor serum urate, and manage comorbidities.
Frequently Asked Questions (FAQs)
1. Should I aspirate a hot, swollen joint that looks typical for gout?
NICE says: Not routinely, if the diagnosis is clinically clear. SIGN says: Yes, wherever possible, to confirm the diagnosis definitively. Takeaway: In primary care, a clinical diagnosis is acceptable, but a low threshold for referral for aspiration is prudent, especially if there is any diagnostic uncertainty or the presentation is a first event.
2. When should I start Urate-Lowering Therapy (ULT)?
NICE says: Offer after the first attack. SIGN says: Discuss after the first attack, but strongly recommend after recurrent attacks. Takeaway: The trend is towards earlier intervention. A detailed discussion with the patient after their first attack is essential, weighing the benefits of prevention against the commitment to lifelong medication.
3. What is the safest way to start allopurinol?
Both guidelines agree on a "start low and go slow" strategy. Takeaway: Initiate at 100mg daily (or 50mg in advanced CKD), and titrate upwards slowly every 4-8 weeks. Always co-prescribe prophylaxis (e.g., colchicine) for the first 6 months to prevent treatment-initiation flares.
4. A patient's gout is flaring badly since starting allopurinol. Should I stop it?
No. Both guidelines are explicit: do not stop ULT during an acute flare. This is a common and expected reaction. Manage the flare with NSAIDs, colchicine, or steroids while continuing the allopurinol. This reinforces the need for effective prophylaxis at initiation.
5. What if a patient cannot tolerate allopurinol?
Both guidelines recommend febuxostat as the second-line agent. Takeaway: Febuxostat is effective and requires no dose adjustment in CKD. Note the MHRA advice regarding a small increased risk of cardiovascular death and use with caution in patients with major pre-existing heart disease. Uricosurics are generally a specialist-only option in the UK.
Source Links
- NICE Guideline NG219 (2022): Gout: diagnosis and management
- SIGN Guideline 176 (2023): Management of Gout (PDF)